如何引证项目

Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy

   
@article{YKXB3518,
	author = {Shao-Wei Weng 和 Tzu-Lun Huang 和 Pei-Yuan Su 和 Pei-Yao Chang 和 Jia-Kang Wang},
	title = {Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy},
	journal = {眼科学报},
	volume = {30},
	number = {4},
	year = {2015},
	keywords = {},
	abstract = {The purpose of this article is to report a case with rubeosis iridis treated by intravitreal aflibercept. A 61-year-old man had iris neovascularization and scanty vitreous hemorrhage secondary to proliferative diabetic retinopathy in the right eye. Neither neovascularization of angle nor elevation of intraocular pressure was found. Single intravitreal aflibercept 2 mg injection was performed. Rubeosis iridis disappeared on the next day. Scattered retinal laser photocoagulation was added 1 week later. There was no recurrence after 3-month follow-up. Aflibercept may serve as another anti-vascular endothelial growth factor (anti-VEGF) for treating rubeosis iridis.},
	url = {https://ykxb.amegroups.com/article/view/3518}
}